Immune response to CMV in solid organ transplant recipients: current concepts and future directions

References

• Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin. Infect. Dis.50(11), 1439–1447 (2010).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein–Barr virus infections. Herpes10(3), 60–65 (2003).
   PubMedGoogle Scholar
• Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med.202(5), 673–685 (2005).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med.357(25), 2601–2614 (2007).
   PubMed Web of Science ®Google Scholar
• Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant.8(10), 2111–2118 (2008).
   PubMed Web of Science ®Google Scholar
• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J. Clin. Invest.121(5), 1673–1680 (2011).
   PubMed Web of Science ®Google Scholar
• Linares L, Sanclemente G, Cervera C et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant. Proc.43(6), 2145–2148 (2011).
   PubMed Web of Science ®Google Scholar
• van Ree RM, de Vries AP, Zelle DM et al. Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients. Med. Sci. Monit.17(11), CR609–CR617 (2011).
   PubMedGoogle Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med.338(24), 1741–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr. Opin. Organ. Transplant.15(4), 492–498 (2010).
   PubMedGoogle Scholar
• Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl Acad. Sci. USA100(26), 15818–15823 (2003).
   PubMed Web of Science ®Google Scholar
• Mayer KD, Mohrs K, Reiley W et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-γ production by CD8 T cells during infection. J. Immunol.180(2), 693–697 (2008).
   PubMedGoogle Scholar
• Pipeling MR, John ER, Orens JB, Lechtzin N, McDyer JF. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J. Infect. Dis.204(11), 1663–1671 (2011).
   PubMedGoogle Scholar
• Hertoghs KM, Moerland PD, van Stijn A et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J. Clin. Invest.120(11), 4077–4090 (2010).
   PubMedGoogle Scholar
• Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J. Hepatol.2(9), 325–336 (2010).
   PubMedGoogle Scholar
• Gerna G, Lilleri D, Chiesa A et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am. J. Transplant.11(11), 2463–2471 (2011).
   PubMed Web of Science ®Google Scholar
• Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol.41(3), 237–241 (2008).
   PubMedGoogle Scholar
• Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin. Infect. Dis.46(5), 732–740 (2008).
   PubMedGoogle Scholar
• Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med.201(7), 1031–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Abate D, Saldan A, Fiscon M et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis.202(4), 585–594 (2010).
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation93(2), 195–200 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant.9(5), 1214–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation91(8), 927–933 (2011).
   PubMedGoogle Scholar
• Snyder LD, Medinas R, Chan C et al. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am. J. Transplant.11(3), 553–560 (2011).
   PubMedGoogle Scholar
• Eid AJ, Brown RA, Arthurs SK et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int.23(5), 506–513 (2010).
   PubMed Web of Science ®Google Scholar
• Lee S, Park JB, Kim EY et al. Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients. Transplant. Proc.43(7), 2636–2640 (2011).
   PubMedGoogle Scholar
• Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol.3(12), 984–993 (2003).
   PubMed Web of Science ®Google Scholar
• van de Berg PJ, Heutinck KM, Raabe R et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J. Infect. Dis.202(5), 690–699 (2010).
   PubMed Web of Science ®Google Scholar
• Krishnan A, Zhou W, Lacey SF, Limaye AP, Diamond DJ, La Rosa C. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transplant. Infect. Dis.12(4), 363–370 (2010).
   PubMed Web of Science ®Google Scholar
• Homs S, Mansour H, Desvaux D et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am. J. Transplant.9(5), 1230–1236 (2009).
   PubMedGoogle Scholar
• Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation71(9), 1287–1294 (2001).
   PubMed Web of Science ®Google Scholar
• Walker JD, Maier CL, Pober JS. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. J. Immunol.182(3), 1548–1559 (2009).
   PubMed Web of Science ®Google Scholar
• Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J. Gastroenterol.14(31), 4849–4860 (2008).
   PubMed Web of Science ®Google Scholar
• Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med.6, 29 (2008).
   PubMedGoogle Scholar
• Sund F, Lidehall AK, Claesson K et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin. Transplant.24(3), 401–409 (2010).
   PubMed Web of Science ®Google Scholar
• Lidehall AK, Sund F, Lundberg T, Eriksson BM, Totterman TH, Korsgren O. T cell control of primary and latent cytomegalovirus infections in healthy subjects. J. Clin. Immunol.25(5), 473–481 (2005).
   PubMed Web of Science ®Google Scholar
• Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res.157(2), 175–179 (2011).
   PubMed Web of Science ®Google Scholar
• Maue AC, Haynes L. CD4+ T cells and immunosenescence – a mini-review. Gerontology55(5), 491–495 (2009).
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Debska-Slizien A, Jankowska M et al. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech. Ageing Dev.131(2), 96–104 (2010).
   PubMed Web of Science ®Google Scholar
• Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am. J. Transplant.5(5), 1065–1070 (2005).
   PubMed Web of Science ®Google Scholar
• Hughes D, Hafferty J, Fulton L et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J. Clin. Virol.41(2), 92–95 (2008).
   PubMed Web of Science ®Google Scholar
• Costa C, Touscoz GA, Bergallo M et al. Non-organ-specific and anti-endothelial antibodies in relation to CMV infection and acute rejection in renal transplant recipients. Clin. Transplant.24(4), 488–492 (2010).
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Tokumoto T, Shirakawa H et al. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transplant. Infect. Dis.13(3), 318–323 (2011).
   PubMedGoogle Scholar
• Saccoccio FM, Sauer AL, Cui X et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine29(15), 2705–2711 (2011).
   PubMed Web of Science ®Google Scholar
• Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin. Infect. Dis.44(10), 1315–1320 (2007).
   PubMedGoogle Scholar
• Kang SH, Abdel-Massih RC, Brown RA, Dierkhising R, Kremers W, Razonable RR. Homozygosity for the Toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J. Infect. Dis.205(4), 639–646 (2012).
   PubMedGoogle Scholar
• Kruger B, Banas MC, Walberer A et al. A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clin. Sci. (Lond.)119(12), 535–544 (2010).
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu. Rev. Immunol.23, 225–274 (2005).
   PubMed Web of Science ®Google Scholar
• Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am. J. Transplant.8(6), 1312–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Hadaya K, de Rham C, Bandelier C et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant.8(12), 2674–2683 (2008).
   PubMed Web of Science ®Google Scholar
• Fildes JE, Walker AH, Williams SG, Yonan N, Leonard CT. CMV infection is associated with the depletion but lack of activation of peripheral blood natural killer cells in a lung transplant cohort. Transplant. Immunol.19(3–4), 235–237 (2008).
   PubMedGoogle Scholar
• Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood104(12), 3664–3671 (2004).
   PubMed Web of Science ®Google Scholar
• Monsivais-Urenda A, Noyola-Cherpitel D, Hernandez-Salinas A et al. Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur. J. Immunol.40(5), 1418–1427 (2010).
   PubMed Web of Science ®Google Scholar
• Guma M, Budt M, Saez A et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood107(9), 3624–3631 (2006).
   PubMedGoogle Scholar
• Lopez-Verges S, Milush JM, Schwartz BS et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA108(36), 14725–14732 (2011).
   PubMed Web of Science ®Google Scholar
• Walker S, Fazou C, Crough T et al.Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transplant. Infect. Dis.9(2), 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant.8(8), 1749–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Lochmanova A, Lochman I, Tomaskova H et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant. Proc.42(9), 3574–3577 (2010).
   PubMedGoogle Scholar
• Uemura T, Riley TR, Khan A et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin. Transplant.25(1), E32–E37 (2011).
   Google Scholar
• Zeevi A, Husain S, Spichty KJ et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am. J. Transplant.7(2), 471–475 (2007).
   PubMedGoogle Scholar
• De Paolis P, Favaro A, Piola A et al. “Immuknow” to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant. Proc.43(4), 1013–1016 (2011).
   PubMedGoogle Scholar
• Ticha O, Stouracova M, Kuman M, Studenik P, Freiberger T, Litzman J. Monitoring of CD38high expression in peripheral blood CD8+ lymphocytes in patients after kidney transplantation as a marker of cytomegalovirus infection. Transplant. Immunol.24(1), 50–56 (2010).
   PubMedGoogle Scholar
• Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis.47(5), 702–711 (2008).
   PubMed Web of Science ®Google Scholar
• Witzke O, Hauser IA, Bartels M et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation93(1), 61–68 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang LF, Wang YT, Tian JH, Yang KH, Wang JQ. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials. Transplant. Infect. Dis.13(6), 622–632 (2011).
   PubMedGoogle Scholar
• La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transplant. Int.24(9), 920–931 (2011).
   PubMedGoogle Scholar
• Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant.8(1), 158–161 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffmann TW, Halimi JM, Buchler M et al. Impact of a polymorphism in the IL-12p40 gene on the outcome of kidney transplantation. Transplant. Proc.41(2), 654–656 (2009).
   PubMedGoogle Scholar
• Hoffmann TW, Halimi JM, Buchler M et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J. Med. Genet.47(1), 54–58 (2010).
   PubMedGoogle Scholar
• Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med.114(7), 525–531 (1991).
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med.360(12), 1191–1199 (2009).
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a Phase 2 randomised placebo-controlled trial. Lancet377(9773), 1256–1263 (2011).
   PubMed Web of Science ®Google Scholar
• Gerna G, Sarasini A, Patrone M et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol.89(Pt 4), 853–865 (2008).
   PubMed Web of Science ®Google Scholar
• Macagno A, Bernasconi NL, Vanzetta F et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol.84(2), 1005–1013 (2010).
   PubMed Web of Science ®Google Scholar
• Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine26(45), 5760–5766 (2008).
   PubMed Web of Science ®Google Scholar
• Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy2(1), 117–130 (2010).
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Cytomegalovirus vaccines: at last, a major step forward. Herpes15(3), 44–45 (2009).
   PubMedGoogle Scholar
• Bernstein DI. Vaccines for cytomegalovirus. Infect. Disord Drug Targets11(5), 514–525 (2011).
   PubMedGoogle Scholar
• Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol.92(Pt 5), 1021–1031 (2011).
   PubMed Web of Science ®Google Scholar
• Zhong J, Khanna R. Delineating the role of CD4+ T cells in the activation of human cytomegalovirus-specific immune responses following immunization with Ad-gBCMVpoly vaccine: implications for vaccination of immunocompromised individuals. J. Gen. Virol.91(Pt 12), 2994–3001 (2010).
   PubMedGoogle Scholar
• Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med.317(17), 1049–1054 (1987).
   PubMed Web of Science ®Google Scholar
• Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin. Transplant.22(1), 89–97 (2008).
   PubMed Web of Science ®Google Scholar
• Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation81(10), 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Ranganathan K, Worley S, Michaels MG et al. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J. Heart Lung Transplant.28(10), 1050–1056 (2009).
   PubMedGoogle Scholar
• Snydman DR, Kistler KD, Ulsh P, Morris J. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients. Transplantation90(12), 1432–1438 (2010).
   PubMedGoogle Scholar
• Fisher RA, Kistler KD, Ulsh P, Bergman GE, Morris J. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation. Transpl. Infect. Dis.14(2), 121–131 (2012).
   PubMedGoogle Scholar
• Brestrich G, Zwinger S, Fischer A et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transplant.9(7), 1679–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am. J. Transplant.11(12), 2613–2626 (2011).
   PubMedGoogle Scholar
• Harkins L, Volk AL, Samanta M et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet360(9345), 1557–1563 (2002).
   PubMed Web of Science ®Google Scholar
• Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res.62(12), 3347–3350 (2002).
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J. Virol.86(2), 854–864 (2012).
   PubMed Web of Science ®Google Scholar
• Couzi L, Levaillant Y, Jamai A et al. Cytomegalovirus-inducedγδ T cells associate with reduced cancer risk after kidney transplantation. J. Am. Soc. Nephrol.21(1), 181–188 (2010).
   PubMed Web of Science ®Google Scholar
• Couzi L, Pitard V, Sicard X et al. Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood119(6), 1418–1427 (2012).
   PubMedGoogle Scholar
• Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation90(4), 412–418 (2010).
   PubMed Web of Science ®Google Scholar
• Osorio JC, Medina RD, Patino N, Ricaurte L, Moreno L, Lozano E. Significance of cytomegalovirus prophylaxis strategies and development of cancer in kidney transplant recipients. Transplant. Proc.43(9), 3380–3382 (2011).
   PubMedGoogle Scholar
• Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ. Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. J. Exp. Med.205(1), 19–24 (2008).
   PubMedGoogle Scholar